LifeMD (LFMD)
Market Price (1/22/2026): $3.63 | Market Cap: $167.6 MilSector: Health Care | Industry: Health Care Technology
LifeMD (LFMD)
Market Price (1/22/2026): $3.63Market Cap: $167.6 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% | Weak multi-year price returns2Y Excs Rtn is -85% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.8% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 30% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.3% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% | High stock price volatilityVol 12M is 104% | |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Health Data Analytics, Show more. | Short seller report | |
| Key risksLFMD key risks include [1] a securities class action lawsuit alleging financial misstatements and [2] disclosed material weaknesses in its internal controls. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 30% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Health Data Analytics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -85% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.8% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.3% |
| High stock price volatilityVol 12M is 104% |
| Short seller report |
| Key risksLFMD key risks include [1] a securities class action lawsuit alleging financial misstatements and [2] disclosed material weaknesses in its internal controls. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
LifeMD (LFMD) stock has lost about 50% since 9/30/2025 because of the following key factors:
1. Delayed Q3 Earnings and Revenue Recognition Issues. LifeMD initially rescheduled its Third Quarter 2025 earnings release from November 6 to November 17, 2025. This delay was attributed to identified corrections related to revenue recognition from prior periods (2023, 2024, and H1 2025), with a cumulative impact of approximately $4.6 million. Such an announcement typically raises investor concerns about financial transparency and reporting integrity, potentially leading to a decline in stock value.
2. Missed Q3 2025 Earnings Estimates and Reduced Full-Year Guidance. When LifeMD eventually reported its Q3 2025 results on November 17, 2025, it posted an Earnings Per Share (EPS) of -$0.10, missing analyst consensus estimates of -$0.06. Additionally, revenue of $60.2 million fell slightly short of analyst expectations of $62.07 million. More critically, the company significantly lowered its full-year 2025 revenue guidance to a range of $192 million to $193 million, a substantial reduction from earlier guidance of $265 million to $275 million provided in March 2025. These financial misses and the downward revision in guidance likely eroded investor confidence, leading to a sharp stock decline. The stock reportedly fell 15% in after-hours trading after the Q3 earnings release and was down 26.43% on November 18, 2025.
Show more
1. Delayed Q3 Earnings and Revenue Recognition Issues. LifeMD initially rescheduled its Third Quarter 2025 earnings release from November 6 to November 17, 2025. This delay was attributed to identified corrections related to revenue recognition from prior periods (2023, 2024, and H1 2025), with a cumulative impact of approximately $4.6 million. Such an announcement typically raises investor concerns about financial transparency and reporting integrity, potentially leading to a decline in stock value.
2. Missed Q3 2025 Earnings Estimates and Reduced Full-Year Guidance. When LifeMD eventually reported its Q3 2025 results on November 17, 2025, it posted an Earnings Per Share (EPS) of -$0.10, missing analyst consensus estimates of -$0.06. Additionally, revenue of $60.2 million fell slightly short of analyst expectations of $62.07 million. More critically, the company significantly lowered its full-year 2025 revenue guidance to a range of $192 million to $193 million, a substantial reduction from earlier guidance of $265 million to $275 million provided in March 2025. These financial misses and the downward revision in guidance likely eroded investor confidence, leading to a sharp stock decline. The stock reportedly fell 15% in after-hours trading after the Q3 earnings release and was down 26.43% on November 18, 2025.
Show more
Stock Movement Drivers
Fundamental Drivers
The -40.1% change in LFMD stock from 10/31/2025 to 1/21/2026 was primarily driven by a -39.4% change in the company's P/S Multiple.| 10312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.91 | 3.54 | -40.1% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 244 | 251 | 2.8% |
| P/S Multiple | 1.1 | 0.7 | -39.4% |
| Shares Outstanding (Mil) | 44 | 46 | -4.0% |
| Cumulative Contribution | -40.2% |
Market Drivers
10/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| LFMD | -40.1% | |
| Market (SPY) | 0.5% | 45.3% |
| Sector (XLV) | 9.7% | 5.1% |
Fundamental Drivers
The -66.0% change in LFMD stock from 7/31/2025 to 1/21/2026 was primarily driven by a -66.3% change in the company's P/S Multiple.| 7312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 10.41 | 3.54 | -66.0% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 233 | 251 | 7.9% |
| P/S Multiple | 1.9 | 0.7 | -66.3% |
| Shares Outstanding (Mil) | 43 | 46 | -7.0% |
| Cumulative Contribution | -66.2% |
Market Drivers
7/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| LFMD | -66.0% | |
| Market (SPY) | 8.7% | 30.3% |
| Sector (XLV) | 21.9% | 22.3% |
Fundamental Drivers
The -36.4% change in LFMD stock from 1/31/2025 to 1/21/2026 was primarily driven by a -46.4% change in the company's P/S Multiple.| 1312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.57 | 3.54 | -36.4% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 193 | 251 | 30.2% |
| P/S Multiple | 1.2 | 0.7 | -46.4% |
| Shares Outstanding (Mil) | 42 | 46 | -9.9% |
| Cumulative Contribution | -37.1% |
Market Drivers
1/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| LFMD | -36.4% | |
| Market (SPY) | 14.9% | 27.4% |
| Sector (XLV) | 9.2% | 11.9% |
Fundamental Drivers
The 78.8% change in LFMD stock from 1/31/2023 to 1/21/2026 was primarily driven by a 112.3% change in the company's Total Revenues ($ Mil).| 1312023 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.98 | 3.54 | 78.8% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 118 | 251 | 112.3% |
| P/S Multiple | 0.5 | 0.7 | 25.7% |
| Shares Outstanding (Mil) | 31 | 46 | -49.2% |
| Cumulative Contribution | 35.5% |
Market Drivers
1/31/2023 to 1/21/2026| Return | Correlation | |
|---|---|---|
| LFMD | 78.8% | |
| Market (SPY) | 74.9% | 26.4% |
| Sector (XLV) | 24.2% | 12.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LFMD Return | -41% | -50% | 327% | -40% | -31% | 4% | -45% |
| Peers Return | -57% | -57% | 69% | 6% | -9% | -5% | -72% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| LFMD Win Rate | 25% | 50% | 67% | 50% | 50% | 100% | |
| Peers Win Rate | 23% | 38% | 55% | 40% | 42% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 0% | |
Max Drawdowns [4] | |||||||
| LFMD Max Drawdown | -42% | -53% | -41% | -51% | -35% | 0% | |
| Peers Max Drawdown | -62% | -68% | -24% | -46% | -29% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HIMS, TDOC, AMWL, GDRX, TALK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/21/2026 (YTD)
How Low Can It Go
| Event | LFMD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.2% | -25.4% |
| % Gain to Breakeven | 2556.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -31.6% | -33.9% |
| % Gain to Breakeven | 46.2% | 51.3% |
| Time to Breakeven | 5 days | 148 days |
| 2018 Correction | ||
| % Loss | -51.8% | -19.8% |
| % Gain to Breakeven | 107.5% | 24.7% |
| Time to Breakeven | 260 days | 120 days |
Compare to HIMS, TDOC, AMWL, GDRX, TALK
In The Past
LifeMD's stock fell -96.2% during the 2022 Inflation Shock from a high on 2/17/2021. A -96.2% loss requires a 2556.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
AI Analysis | Feedback
Hims & Hers for chronic and specialty care, with a strong emphasis on weight management.
Teladoc for direct-to-consumer chronic care and online prescriptions.
AI Analysis | Feedback
- Weight Management Program: A comprehensive telehealth service offering personalized treatment plans, including GLP-1 medications, for sustainable weight loss.
- Primary Care Telehealth: Provides virtual consultations with licensed medical professionals for a wide range of common health concerns, prescriptions, and referrals.
- Men's Health Telehealth: Offers discreet online consultations and prescribed treatments for specific conditions affecting men, such as erectile dysfunction and hair loss.
AI Analysis | Feedback
LifeMD (symbol: LFMD) primarily sells its telehealth services and related products directly to individual consumers, operating under a direct-to-consumer (DTC) model. Therefore, it does not have major corporate customers that account for a significant portion of its revenue.
The company serves the following categories of individual customers:
- Men seeking specialized health solutions: This category includes individuals utilizing LifeMD's platforms (such as RexMD) for conditions like erectile dysfunction, hair loss, and testosterone deficiency, often involving virtual consultations and prescription medications delivered directly.
- Individuals pursuing physician-led weight management: LifeMD offers comprehensive weight loss programs that involve virtual consultations with healthcare providers, personalized treatment plans, and access to prescription medications (including GLP-1s) when clinically appropriate.
- General telehealth users seeking virtual primary care and other specialized services: This category encompasses individuals utilizing LifeMD for broader virtual healthcare needs, including general medical consultations, preventative care, and certain women's health services.
AI Analysis | Feedback
nullAI Analysis | Feedback
Justin Schreiber Chairman & CEO
As a co-founder of LifeMD, Justin Schreiber has played an essential role in the company's formation, growth, and development, serving as CEO and Chairman of the board of directors since 2018. He is an experienced venture investor and the founder and president of JLS Ventures, which provides capital markets advisory services. Schreiber also co-founded and currently serves on the board of Quantum Computing Inc. (OTCQB: QUBT). His prior experience includes working for a global healthcare consulting firm and beginning his career at Gain Capital Group, focusing on foreign currency trading.
Marc Benathen Chief Financial Officer
Marc Benathen has served as LifeMD's Chief Financial Officer since 2021. He brings over 18 years of financial, strategy, direct-to-consumer, and operating leadership experience to the role. Prior to joining LifeMD, Benathen was the SVP and Chief Financial Officer for Blink Fitness, a national health and wellness brand. He also held several senior financial and operating positions with ANN, Inc., the then-public company parent of Ann Taylor, LOFT, and Lou & Grey.
Stefan Galluppi Chief Innovation Officer
Stefan Galluppi is a co-founder of LifeMD and has served as its Chief Technology Officer since co-founding the company in 2016. He brings more than a decade of experience in building technology platforms for direct-to-consumer marketing campaigns. Galluppi previously served as Chief Technology Officer of Runaway Products, a DRTV-driven marketing firm, and co-founded NT1, a digital marketing, web development, and design company. He also previously worked as a commodities trader at CQR Capital.
Shayna Webb Dray Chief Operating Officer
Shayna Webb Dray was appointed Chief Operating Officer in July 2025, bringing over 15 years of experience in transforming operations within high-growth and established organizations. She joined LifeMD in 2021 as the Head of Supply Chain and Procurement, where she spearheaded the creation of a comprehensive supply chain strategy. In 2023, she was named Senior Vice President of Operations and was responsible for the successful launch, operationalization, and scaling of the company's weight management program. Before LifeMD, Webb Dray served as Executive Director of Operations at Kaplan Publishing, a Graham Holdings subsidiary.
Nick Alvarez Chief Acquisition Officer
Nick Alvarez has served as LifeMD's Chief Acquisition Officer since 2018, overseeing the company's customer acquisition efforts, including advertising strategy and media buying. He is an accomplished executive in the digital marketing space. Prior to LifeMD, Alvarez was the head media buyer at Cheviot Capital and a digital marketing specialist at Internet Brands, where he was responsible for brands such as Lawyers.com and Carsdirect.com, managing over $100 million in paid media budgets.
AI Analysis | Feedback
The key risks to LifeMD's business (LFMD) include a securities class action lawsuit stemming from alleged financial misstatements, broader regulatory and governance challenges, and intense market competition within the GLP-1 therapy segment.
- Securities Class Action Lawsuit and Operational Challenges: LifeMD is currently facing a securities class action lawsuit. This legal action alleges financial misstatements and misleading disclosures, specifically regarding rising customer acquisition costs within its RexMD and obesity treatment segments. These issues contributed to a significant 44.8% stock price decline following the company's Q2 2025 earnings report, which revealed underperformance and a revised, lower financial guidance.
- Regulatory and Governance Risks: The company faces intensifying regulatory scrutiny in the telehealth sector, particularly concerning data privacy. Evidence of this includes a data privacy settlement related to sharing patient health information with third-party platforms. Furthermore, LifeMD has disclosed material weaknesses in its internal controls, including IT general controls and business process oversight, indicating governance challenges.
- Market Competition and Affordability in GLP-1 Therapies: LifeMD's weight management programs have been affected by elevated customer acquisition costs and affordability barriers for GLP-1 therapies. The rapidly growing GLP-1 market is experiencing increased competition and regulatory oversight, which could lead to slower growth for LifeMD's GLP-1 program.
AI Analysis | Feedback
The increasing entry and expansion of large, well-capitalized technology and retail companies into the direct-to-consumer (DTC) telehealth market, specifically targeting conditions like weight loss and men's health. These companies, such as Amazon with its Amazon Clinic, leverage their immense brand recognition, vast customer bases, and robust logistical capabilities to offer virtual care and prescription delivery, directly competing with and potentially undercutting specialized DTC telehealth providers like LifeMD.
AI Analysis | Feedback
LifeMD (symbol: LFMD) operates within several addressable markets for its main products and services, primarily in the U.S.
- U.S. Telehealth Market: The overall U.S. telehealth market is estimated at $170 billion. Projections suggest the U.S. direct-to-consumer telehealth services market alone could reach $9.53 billion by 2030. The U.S. telehealth market is also anticipated to grow at a compound annual growth rate (CAGR) of 24.68% through 2030 and 23.84% through 2034.
- GLP-1 Weight Management Program: The global GLP-1 market for weight management is projected to reach or exceed $100 billion in annual revenues by 2030, a significant increase from $6 billion in 2023. J.P. Morgan Research also projects this market to increase from over $13 billion to over $100 billion by 2030.
- Women's Health: Specifically addressing menopause and osteoporosis, this represents a projected market opportunity of $60 billion to $70 billion by 2030 in the U.S. The osteoporosis market alone could reach $18.8 billion by 2030.
- Men's Health: LifeMD's RexMD brand focuses on men's health. While it is a significant offering, a specific addressable market size for men's health services was not readily available in the provided information.
- Dermatology and Allergy & Asthma: No specific addressable market sizes for these individual product categories were found in the provided search results.
AI Analysis | Feedback
LifeMD (LFMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Product Diversification and Expansion into New Therapeutic Areas: LifeMD plans to expand its offerings into new areas such as women's health, behavioral health, and hormonal health, moving beyond its current focus to diversify its revenue streams. This includes the nationwide launch of a behavioral health offering and the acquisition of a women's health practice, with a new women's health program anticipated to launch by the end of Q3 2025.
- Continued Growth in Core Telehealth Segments: The company's telehealth segment remains a primary growth driver, with strong year-over-year revenue increases. This growth is particularly bolstered by the strong performance of weight management programs.
- Expansion of Insurance Coverage, Notably Medicare: LifeMD is actively expanding its fee-for-service Medicare coverage, aiming to reach a substantial number of beneficiaries across many states. This expansion is expected to broaden the company's market reach and enhance revenue through improved patient retention.
- Launch of New Subscription-Based Care Models: The introduction of LifeMDPlus, a subscription-based care model, is identified as a significant upcoming initiative designed to attract and retain customers.
- Strategic Partnerships for Enhanced Medication Access: LifeMD has expanded its partnerships with pharmaceutical companies like LillyDirect and NovoCare. These collaborations aim to improve patient access to GLP-1 medications, thereby strengthening LifeMD's competitive position in virtual obesity care.
AI Analysis | Feedback
Share Issuance
- LifeMD commenced an underwritten registered public offering of common stock in September 2021, with net proceeds intended for debt repayment, working capital, new patient customer acquisition expenses, and capital expenditures.
- The diluted weighted average number of common shares outstanding for LifeMD increased by 22% during the third quarter of fiscal year 2024 compared to the prior year, and by a remarkable 291% over the last five years.
- In April 2025, LifeMD issued 100,000 shares of its common stock as part of the acquisition of key assets from Optimal Human Health MD, with 50,000 shares issued at closing and the remaining 50,000 on the first anniversary of the closing.
Inbound Investments
- In late 2023, Medifast made a $10 million equity investment in LifeMD common stock and paid an additional $10 million upfront as a collaboration fee.
- LifeMD has secured funding over two rounds, with its most recent funding round taking place in August 2020.
Outbound Investments
- LifeMD acquired key assets from Optimal Human Health MD in April 2025 for approximately $0.6 million, partially paid through the issuance of common stock, signifying its official entry into the women's health market.
- In November 2025, LifeMD divested its majority ownership in WorkSimpli Software LLC in a transaction valuing the SaaS platform at approximately $65 million, receiving about $22 million in cash at closing.
- The sale agreement for WorkSimpli includes potential additional payments of up to $28 million if specific growth and operational targets are achieved over the next three years.
Capital Expenditures
- Capital expenditures for LifeMD were reported as $12.89 million, $8.73 million, $11.54 million, and $12.78 million for the years 2021, 2022, 2023, and 2024 respectively.
- A portion of the net proceeds from the September 2021 public offering was designated for capital expenditures.
- LifeMD has made significant long-term investments in developing its human capital, technology, brand awareness, omni-channel marketing, and operations infrastructure to support its growth as a healthcare-focused company.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| LifeMD Earnings Notes | 12/16/2025 | |
| Would You Still Hold LifeMD Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for LifeMD
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.18 |
| Mkt Cap | 0.8 |
| Rev LTM | 533 |
| Op Inc LTM | -1 |
| FCF LTM | 52 |
| FCF 3Y Avg | 49 |
| CFO LTM | 96 |
| CFO 3Y Avg | 88 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.3% |
| Rev Chg 3Y Avg | 12.5% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | -0.4% |
| Op Mgn 3Y Avg | -7.9% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 8.3% |
| CFO/Rev 3Y Avg | 8.8% |
| FCF/Rev LTM | 2.7% |
| FCF/Rev 3Y Avg | 3.0% |
Price Behavior
Price Behavior
| Market Price | $3.54 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 11/15/2018 | |
| Distance from 52W High | -76.5% | |
| 50 Days | 200 Days | |
| DMA Price | $3.85 | $7.26 |
| DMA Trend | down | down |
| Distance from DMA | -8.0% | -51.2% |
| 3M | 1YR | |
| Volatility | 81.0% | 103.9% |
| Downside Capture | 558.77 | 224.87 |
| Upside Capture | 196.28 | 156.15 |
| Correlation (SPY) | 45.3% | 27.6% |
LFMD Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.19 | 3.05 | 2.37 | 2.54 | 1.49 | 1.55 |
| Up Beta | 1.70 | 0.51 | -0.04 | 1.81 | 1.12 | 0.98 |
| Down Beta | 0.55 | 3.66 | 2.98 | 3.16 | 1.43 | 1.57 |
| Up Capture | 336% | 102% | 61% | -3% | 193% | 858% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 7 | 13 | 23 | 52 | 121 | 377 |
| Down Capture | 498% | 434% | 342% | 303% | 148% | 112% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 14 | 27 | 39 | 72 | 127 | 355 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LFMD | |
|---|---|---|---|---|
| LFMD | -23.5% | 103.9% | 0.24 | - |
| Sector ETF (XLV) | 14.5% | 17.4% | 0.62 | 11.7% |
| Equity (SPY) | 15.8% | 19.3% | 0.63 | 27.4% |
| Gold (GLD) | 79.5% | 20.4% | 2.78 | 2.8% |
| Commodities (DBC) | 5.7% | 15.3% | 0.16 | 12.0% |
| Real Estate (VNQ) | 5.8% | 16.7% | 0.17 | 15.6% |
| Bitcoin (BTCUSD) | -14.7% | 39.8% | -0.31 | 23.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LFMD | |
|---|---|---|---|---|
| LFMD | -11.9% | 96.4% | 0.32 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 14.7% |
| Equity (SPY) | 14.0% | 17.1% | 0.66 | 27.6% |
| Gold (GLD) | 20.8% | 15.7% | 1.07 | 3.4% |
| Commodities (DBC) | 11.4% | 18.7% | 0.49 | 6.4% |
| Real Estate (VNQ) | 5.7% | 18.8% | 0.21 | 18.2% |
| Bitcoin (BTCUSD) | 19.0% | 58.0% | 0.53 | 18.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LFMD | |
|---|---|---|---|---|
| LFMD | -2.3% | 101.9% | 0.45 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 16.7% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 25.3% |
| Gold (GLD) | 15.7% | 14.9% | 0.87 | 4.5% |
| Commodities (DBC) | 8.2% | 17.6% | 0.38 | 4.0% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 16.1% |
| Bitcoin (BTCUSD) | 70.3% | 66.7% | 1.09 | 16.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/17/2025 | -13.5% | -16.1% | -31.5% |
| 8/5/2025 | -44.8% | -42.3% | -47.0% |
| 3/10/2025 | 30.6% | 33.7% | 12.9% |
| 1/19/2022 | -4.3% | -8.5% | 16.2% |
| 4/1/2021 | 9.1% | -6.2% | -38.6% |
| 1/19/2021 | 9.0% | 128.6% | 278.2% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 3 | 4 | 3 |
| Median Positive | 9.1% | 81.2% | 16.2% |
| Median Negative | -13.5% | -12.3% | -38.6% |
| Max Positive | 30.6% | 128.6% | 278.2% |
| Max Negative | -44.8% | -42.3% | -47.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/17/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/05/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/06/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/11/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/07/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/07/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/08/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 03/11/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/08/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/09/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/12/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/22/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/10/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/11/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/13/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/07/2022 | 10-K (12/31/2021) |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Friedeman, Jessica | Chief Marketing Officer | Direct | Sell | 12112025 | 3.61 | 15,000 | 54,158 | 740,152 | Form |
| 2 | Alvarez, Nicholas P | Chief Acquisition Officer | Direct | Sell | 9122025 | 5.92 | 75,000 | 443,760 | 3,579,664 | Form |
| 3 | Schreiber, Justin | Chairman and CEO | by Schreiber Holdings LLC | Sell | 8052025 | 9.99 | 25,000 | 249,690 | 24,726,511 | Form |
| 4 | Schreiber, Justin | Chairman and CEO | by Schreiber Holdings LLC | Sell | 7032025 | 13.38 | 25,000 | 334,458 | 33,455,396 | Form |
| 5 | Benathen, Marc David | Chief Financial Officer | Direct | Sell | 6182025 | 13.09 | 75,000 | 981,945 | 5,100,275 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.